Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients

Summary

This study will evaluate the efficacy of oral Foipan® (camostat mesilate) compared with the current standard of care in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with mild-moderate COVID-19 disease. Patients will attend 4 study visits over a period of up to 28 days.

Timeline

Start

2020-12-19

Primary completion

2021-05-15

Completion

2021-05-15

Drugs

Indications